Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Blog by Professor Christiane Dolecek. Antimicrobial resistance is a critical problem in enteric fever. Drug-resistant infections can have severe consequences, and slowing their spread requires our urgent attention. The most important intervention is to reduce the number of infections; vaccines are a critical tool, alongside surveillance and diagnosis. To achieve this control, strong partnerships between WHO, governments, NGOs, academia, private sector and communities are needed.

Local women collecting water in large jars. © Deparment for International Development / Rafiqur Rahman Raqu

Similar stories

PLATCOV researchers find dramatic acceleration of SARS CoV2 viral clearance rates since Sept 2021

Running continuously since Sept 2021, the PLATCOV trial has randomised over 1700 patients presenting with COVID19 infections. Work by PLATCOV’s Dr Phrutsamon Wongnak published in the Lancet Infectious Diseases has shown that rates of oropharyngeal viral clearance have accelerated dramatically since the trial started: A SARS CoV2 viral clearance half-life in untreated patients of around 16 hours In Sept 2021 had reduced to around 9 hours by Oct 2023. The results highlight the importance of pharmacometric platform trials like PLATCOV, so that we are prepared for the next pandemic.